Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

A legfontosabb adatok

Ki végzi
Denali Therapeutics Inc.
Hol
Chapel Hill, Oakland és Pittsburgh (Egyesült Államok)Mind a 3 helyszín megnézéseMég 2 másik országban, 3 helyszínen
Azonosító
Állapot
Befejeződött
Résztvevők
18 fő vett részt
Kezdés
2019. okt. 23.
Befejezés
2024. márc. 1.
A vizsgálat típusa
Megfigyeléses, 6 csoport
A regiszteradat frissítve
2024. június 10.

Ki vehet részt

Életkor
Legfeljebb 30 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants aged 2 through 10 years
  • nMPS II subgroup: participants with a development quotient (DQ) <85 and/or a decline of at least 7.5 points in DQ, assessed at least 6 months apart, or with the same genetic mutation as a blood relative with confirmed nMPS II
  • Participants aged 2 through 30 years
  • nMPS II subgroup: patients with an age-adjusted DQ <85 and/or a decline of 10 points or more in DQ in the previous 6 months or more, or with the same genetic mutation as a blood relative with confirmed nMPS II
  • Scheduled to undergo general anesthesia or CSF sampling for non-study-related medical reasons and parent(s)/legally authorized representative consent to donate CSF for research purposes during that procedure, or an adult patient is able to provide consent and agrees to participation in the study for CSF collection/donation
  • nMPS II participants aged <8 years
  • nnMPS II participants aged 6 to 17 years
  • Participants aged ≤ 3 years
  • Have undetermined MPS II phenotype; Do not have a large deletion(s) or rearrangement(s) in the IDS gene or other definitive mutation indicative of nMPS II; Do not have a DQ < 85 at the screening/baseline neurocognitive assessment and/or a documented decline of at least 7.5 points in DQ in the previous 6 to 18 months; Do not have the same IDS gene variant as a blood relative with confirmed nMPS II or nnMPS II
  • nMPS II participants aged 1 to 17 years
  • Have received an MPS II gene therapy or allogeneic HSCT > 12 months prior to screening
  • Have a post-HSCT or post-gene therapy DQ < 85 at the screening/baseline neurocognitive assessment and/or a documented decline of at least 7.5 points in DQ in the previous 6 to 18 months

Ki nem vehet részt

  • Have received any central nervous system (CNS)-targeted MPS II investigational therapy within the previous 6 months
  • Have unstable medical condition that would make participation in the study unsafe or would interfere with necessary medical care

Helyszínek itt: Egyesült Államok

Még 2 másik országban, 3 helyszínen

  • UNC Children's Research InstituteChapel Hill, Egyesült Államok
  • UCSF Benioff Children s HospitalOakland, Egyesült Államok
  • UPMC Children's Hospital of PittsburghPittsburgh, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a six-part prospective, multicenter, multiregional observational study of patients with mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, to assess biomarkers potentially related to disease severity and/or treatment response and prospectively assess the progression of disease in participants with MPS II who are aged ≤30 years at the time of enrollment.

A vizsgálat 6 csoportja

  • Part 1

    Participants from 2 through 10 years of age who have MPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 2

    Participants from 2 through 30 years of age who have MPS II; Part 2 will entail a single collection of cerebrospinal fluid (CSF), urine, and blood. Clinical outcome assessments are optional in Part 2 for participants aged 18 years or younger; no clinical assessments are planned for participants older than 18 years.

  • Part 3

    Participants \<8 years of age who have the neuronopathic form of mucopolysaccharidosis type II (nMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 4

    Participants 6 to 17 years of age with the non-neuronopathic form of mucopolysaccharidosis type II (nnMPS II). Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 5

    Participants ≤3 years of age with an undetermined MPS II phenotype. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted.

  • Part 6

    Participants from 1 to 17 years of age with nMPS II. Clinical, neurocognitive, laboratory, and biomarker assessments will be conducted. Part 6 will also include a single collection of CSF.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Prospective, Longitudinal Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome
A regiszteradat frissítve
2024. június 10.